GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (WBO:BNTX) » Definitions » Return-on-Tangible-Equity

BioNTech SE (WBO:BNTX) Return-on-Tangible-Equity : -6.66% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is BioNTech SE Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. BioNTech SE's annualized net income for the quarter that ended in Mar. 2024 was €-1,260 Mil. BioNTech SE's average shareholder tangible equity for the quarter that ended in Mar. 2024 was €18,929 Mil. Therefore, BioNTech SE's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was -6.66%.

The historical rank and industry rank for BioNTech SE's Return-on-Tangible-Equity or its related term are showing as below:

WBO:BNTX' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -240.49   Med: 3.39   Max: 158.44
Current: 0.59

During the past 8 years, BioNTech SE's highest Return-on-Tangible-Equity was 158.44%. The lowest was -240.49%. And the median was 3.39%.

WBO:BNTX's Return-on-Tangible-Equity is ranked better than
80.64% of 1312 companies
in the Biotechnology industry
Industry Median: -47.715 vs WBO:BNTX: 0.59

BioNTech SE Return-on-Tangible-Equity Historical Data

The historical data trend for BioNTech SE's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNTech SE Return-on-Tangible-Equity Chart

BioNTech SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial -61.53 1.89 159.58 59.85 4.78

BioNTech SE Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.11 -3.88 3.36 9.66 -6.66

Competitive Comparison of BioNTech SE's Return-on-Tangible-Equity

For the Biotechnology subindustry, BioNTech SE's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioNTech SE's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioNTech SE's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where BioNTech SE's Return-on-Tangible-Equity falls into.



BioNTech SE Return-on-Tangible-Equity Calculation

BioNTech SE's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=930.3/( (19835.9+19079.3 )/ 2 )
=930.3/19457.6
=4.78 %

BioNTech SE's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-1260.4/( (19079.3+18777.8)/ 2 )
=-1260.4/18928.55
=-6.66 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


BioNTech SE  (WBO:BNTX) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


BioNTech SE Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of BioNTech SE's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


BioNTech SE (WBO:BNTX) Business Description

Industry
Address
An der Goldgrube 12, Mainz, RP, DEU, D-55131
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.

BioNTech SE (WBO:BNTX) Headlines

From GuruFocus